A detailed history of Redmile Group, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,721,054 shares of STOK stock, worth $60.7 Million. This represents 4.16% of its overall portfolio holdings.

Number of Shares
4,721,054
Previous 5,073,049 6.94%
Holding current value
$60.7 Million
Previous $68.5 Million 6.87%
% of portfolio
4.16%
Previous 2.7%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.03 - $17.52 $3.88 Million - $6.17 Million
-351,995 Reduced 6.94%
4,721,054 $63.8 Million
Q1 2024

May 15, 2024

BUY
$4.12 - $14.17 $10.1 Million - $34.7 Million
2,447,543 Added 93.22%
5,073,049 $68.5 Million
Q4 2023

Feb 14, 2024

SELL
$3.37 - $5.4 $4.48 Million - $7.18 Million
-1,329,682 Reduced 33.62%
2,625,506 $13.8 Million
Q2 2023

Aug 14, 2023

SELL
$7.93 - $13.82 $1.51 Million - $2.63 Million
-190,208 Reduced 4.59%
3,955,188 $42 Million
Q1 2023

May 15, 2023

BUY
$7.65 - $10.38 $26.8 Million - $36.4 Million
3,502,966 Added 545.27%
4,145,396 $34.5 Million
Q4 2022

Feb 14, 2023

SELL
$7.07 - $15.69 $1.37 Million - $3.03 Million
-193,400 Reduced 23.14%
642,430 $5.93 Million
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $14.5 Million - $26.1 Million
-1,157,438 Reduced 58.07%
835,830 $10.7 Million
Q2 2022

Aug 15, 2022

SELL
$10.36 - $23.93 $322,196 - $744,223
-31,100 Reduced 1.54%
1,993,268 $26.3 Million
Q1 2022

May 16, 2022

SELL
$17.19 - $26.1 $3.82 Million - $5.8 Million
-222,300 Reduced 9.89%
2,024,368 $42.6 Million
Q4 2021

Feb 14, 2022

SELL
$18.11 - $30.72 $2.45 Million - $4.16 Million
-135,290 Reduced 5.68%
2,246,668 $53.9 Million
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $1.81 Million - $2.64 Million
-76,600 Reduced 3.12%
2,381,958 $60.6 Million
Q2 2021

Aug 16, 2021

SELL
$30.53 - $41.09 $2.61 Million - $3.51 Million
-85,504 Reduced 3.36%
2,458,558 $82.8 Million
Q1 2021

May 17, 2021

SELL
$36.08 - $69.81 $5.13 Million - $9.93 Million
-142,172 Reduced 5.29%
2,544,062 $98.8 Million
Q4 2020

Feb 16, 2021

BUY
$33.62 - $61.93 $4.6 Million - $8.47 Million
136,728 Added 5.36%
2,686,234 $166 Million
Q3 2020

Nov 16, 2020

BUY
$22.23 - $37.48 $1.05 Million - $1.77 Million
47,200 Added 1.89%
2,549,506 $85.4 Million
Q2 2020

Aug 14, 2020

BUY
$20.26 - $29.73 $6.81 Million - $10 Million
336,368 Added 15.53%
2,502,306 $59.6 Million
Q1 2020

May 15, 2020

BUY
$16.8 - $34.15 $19.2 Million - $39.1 Million
1,145,160 Added 112.19%
2,165,938 $49.6 Million
Q4 2019

Feb 14, 2020

BUY
$20.01 - $30.79 $66,033 - $101,607
3,300 Added 0.32%
1,020,778 $28.9 Million
Q3 2019

Nov 14, 2019

SELL
$20.53 - $37.72 $88,894 - $163,327
-4,330 Reduced 0.42%
1,017,478 $21.9 Million
Q2 2019

Aug 14, 2019

BUY
$25.53 - $29.17 $26.1 Million - $29.8 Million
1,021,808 New
1,021,808 $29.8 Million

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $507M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.